These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 37218137)
1. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137 [TBL] [Abstract][Full Text] [Related]
2. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
3. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326 [TBL] [Abstract][Full Text] [Related]
6. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer. Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N Cells; 2022 May; 11(10):. PubMed ID: 35626731 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
9. GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. Park J; Purushothaman B; Hong S; Choi M; Jegal KH; Park M; Song JM; Kang KW Life Sci; 2024 Jul; 348():122681. PubMed ID: 38697281 [TBL] [Abstract][Full Text] [Related]
10. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
12. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460 [TBL] [Abstract][Full Text] [Related]
13. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189 [TBL] [Abstract][Full Text] [Related]
15. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors. Ménard L; Floc'h N; Martin MJ; Cross DAE Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874 [TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR. Yu T; Xia Q; Gong T; Wang J; Zhong D Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227 [TBL] [Abstract][Full Text] [Related]
18. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds. Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314 [TBL] [Abstract][Full Text] [Related]
19. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]